RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
BLOOD
Collezione ASL Biella

Items : 13

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi in Blood

2024
ASL Biella

Ferrero S; Del Giudice I; Galimberti S; Gattei V; Marcheselli L; Genuardi E; Drandi D; Pironti M; Dogliotti I; Civita AM; Della Starza I; Assanto GM; Guerrini F; Bono C; Bomben R; Boccomini C; Farina L; Olivieri J; Arcaini L; Cavallo F; Ballerini F; Margiotta Casaluci G; Zilioli VR; Zanni M; Musuraca G; Merli A; Bianchi B; Bolis S; Pavone V; et alii...

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL) in Blood

2024
ASL Biella

Ladetto M; Tavarozzi R; Ku M; Arcaini L; Boccomini C; Casadei B; Chiarenza A; Conconi A; Del Giudice I; Merli M; Nizzoli ME; Luminari S;

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy in Blood

2024
ASL Biella

Bommier C; Zucca E; Chevret S; Conconi A; Nowakowski G; Maurer MJ; Cerhan JR; Thieblemont C; Lambert J;

Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma in Blood

2022
ASL Biella

Bommier C; Conconi A; Zucca E; Nowakowski GS; Cerhan JR; Thieblemont C; Lambert J;

Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up in Blood

2022
ASL Biella

Cilloni D; Umurungi J; Bonuomo V; Itri F; Rotolo C; Marini S; Lunghi M; Castelli A; Fava C; Saglio G; Cignetti A; Petiti J;

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) in Blood

2022
ASL Torino 4
ASL Biella

Lanino L; Salutari P; Perego A; Fattizzo B; Riva M; Ubezio M; Musto P; Cilloni D; Oliva EN; Voso MT; Pelizzari AM; Poloni A; Capodanno I; Elena C; Fozza C; Pane F; Breccia M; De Gobbi M; Di Bassiano F; Barraco D; Crisà E; Ferrero D; Frairia C; Vaccarino A; Griguolo D; Paolini S; Quintini M; Sessa M; Turrini M; et alii...

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study in Blood

2022
ASL Biella

Bosi A; Fattizzo B; Rizzo L; Ferrari S; Lussana F; Borin LM; Castelli A; Bianchi P; Barcellini W; Cairoli R; Molteni A; Riva M;

Clinical relevance of clonal hematopoiesis in persons aged ?80 years in Blood

2021
ASL Biella

Rossi M; Meggendorfer M; Zampini M; Tettamanti M; Riva E; Travaglino E; Bersanelli M; Mandelli S; Antonella Galbussera A; Mosca E; Saba E; Chiereghin C; Manes N; Milanesi C; Ubezio M; Morabito L; Peano C; Soldà G; Asselta R; Duga S; Selmi C; De Santis M; Malik K; Maggioni G; Bicchieri M; Campagna A; Tentori CA; Russo A; Civilini E; et alii...

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) in Blood

2021
ASL Biella

Benevolo G; Ferrero S; Villivà N; Castiglione A; Monaco F; Boccomini C; Cabras MG; Califano C; Casula P; Cavallo F; Conconi A; Drandi D; Gaidano G; Gregorini AI; Felici S; Ferrante M; Mannina D; Molinari AL; Musto P; Musuraca G; Merli M; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

Myelodysplastic syndromes with hypocellular marrow: Clinical characteristics and evaluation of outcome in Blood

2018
ASL Biella

Santini V; Gioia DM; Masiera E; Poloni A; Ferrero D; Fragasso A; Finelli C; Salvi F; Gaidano G; Oliva EN; Catarini M; Cametti G; Bonferroni M; Danise P; Tassara R; Allione B; Cilloni D; Castelli A; Centurioni R; Ciravegna G; Visani G; Musto P; Balleari E; Boveri E; Ponzoni M; Gianelli U; Della Porta MG;

Clinical and molecular results of the phase II BRB (bendamustine, rituximab and bortezomib) trial of the fondazione italiana linfomi (FIL) for relapsed/refractory waldenström macroglobulinemia patients in Blood

2018
ASL Biella

Benevolo G; Ferrero S; Andriani A; Castiglione A; Baraldi A; Boccomini C; Cabras MG; Califano C; Cavallo F; Conconi A; Curreli L; Drandi D; Gaidano G; Felici S; Ferrante M; Mannina D; Merli M; Molinari AL; Musto P; Musuraca G; Rossi FG; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

IELSG-38: A phase II study of chlorambucil in combination with rituximab followed by maintenance therapy with subcutaneous rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) in Blood

2017
ASL Biella

Stathis A; Gregorini A; Gressin R; Orsucci L; Perrot A; Tani M; Coiffier B; Musuraca G; Guieze R; Marino D; Gini G; Ferrari A; Gyan E; Morschhauser F; Palombi F; Cavallo F; Gouill SL; Tilly H; Salvi F; Conconi A; Cabras MG; Capochiani E; Califano C; Molinari AL; Pulsoni A; Ielmini N; Luminari S; Cavalli F; Zucca E; et alii...

Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project in Blood

2010
ASL Biella

Sant M; Allemani C; Tereanu C; De Angelis R; Capocaccia R; Visser O; Marcos-Gragera R; Maynadié M; Simonetti A; Lutz J-M; Berrino F; Hackl M; Holub J; Maynadie M; Holleczek B; Tryggvadottir L; Comber H; Bellù F; Giacomin A; Ferretti S; Crocetti E; Serraino D; Vercelli M; Federico M; Fusco M; Michiara M; Tumino R; Mangone L; Falcini F; et alii...